Overview

The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)

Status:
Completed
Trial end date:
2014-08-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) profile of elbasvir (MK-8742) after a single dose to participants with mild, moderate, or severe hepatic insufficiency compared with healthy controls.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborator:
Celerion